Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?

Michael G. White; Brian Badgwell

doi:10.1245/s10434-021-11253-x

Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	6561-6564
Number of pages	4
Journal	Annals of surgical oncology
Volume	29
Issue number	11
DOIs	https://doi.org/10.1245/s10434-021-11253-x
State	Published - Oct 2022

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1245/s10434-021-11253-x

Cite this

White, M. G., & Badgwell, B. (2022). Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone? Annals of surgical oncology, 29(11), 6561-6564. https://doi.org/10.1245/s10434-021-11253-x

Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone? / White, Michael G.; Badgwell, Brian.
In: Annals of surgical oncology, Vol. 29, No. 11, 10.2022, p. 6561-6564.

Research output: Contribution to journal › Article › peer-review

White, MG & Badgwell, B 2022, 'Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?', Annals of surgical oncology, vol. 29, no. 11, pp. 6561-6564. https://doi.org/10.1245/s10434-021-11253-x

White MG , Badgwell B. Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone? Annals of surgical oncology. 2022 Oct;29(11):6561-6564. doi: 10.1245/s10434-021-11253-x

White, Michael G. ; Badgwell, Brian. / Oncologic Components of HIPEC : Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?. In: Annals of surgical oncology. 2022 ; Vol. 29, No. 11. pp. 6561-6564.

@article{6471ba19aac94171b623792914f313fd,

title = "Oncologic Components of HIPEC: Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?",

author = "White, {Michael G.} and Brian Badgwell",

year = "2022",

month = oct,

doi = "10.1245/s10434-021-11253-x",

language = "English (US)",

volume = "29",

pages = "6561--6564",

journal = "Annals of surgical oncology",

issn = "1068-9265",

publisher = "Springer New York",

number = "11",

}

TY - JOUR

T1 - Oncologic Components of HIPEC

T2 - Key Question: In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?

AU - White, Michael G.

AU - Badgwell, Brian

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85122706213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122706213&partnerID=8YFLogxK

U2 - 10.1245/s10434-021-11253-x

DO - 10.1245/s10434-021-11253-x

M3 - Article

C2 - 34994900

AN - SCOPUS:85122706213

SN - 1068-9265

VL - 29

SP - 6561

EP - 6564

JO - Annals of surgical oncology

JF - Annals of surgical oncology

IS - 11

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this